Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The awards cover options to purchase up to 290,100 shares and restricted stock units covering 92,300 shares, with service-based vesting.

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 16 newly hired employees as a material inducement to accept employment.

The awards comprise options to purchase up to 290,100 shares and restricted stock units covering 92,300 shares. The option exercise price equals the stock’s closing price on October 20, 2026. Options have a ten-year term and vest over four years: 25% on the first anniversary of each employee’s start date, followed by 12 equal quarterly installments. Restricted stock units vest in four equal annual installments from each employee’s start date. Both schedules require continued service through the applicable vesting dates. The grants fall under Dyne’s 2024 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options to purchase up to 290,100 shares create potential dilution; exercise price equals the October 20, 2026 closing price.
• Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 92,300 shares create potential dilution as they vest.

Key Figures

Newly hired employees: 16 employees Stock options: Up to 290,100 shares Restricted stock units: 92,300 shares +3 more

Newly hired employees

16 employees

Recipients of inducement equity awards

Stock options

Up to 290,100 shares

Aggregate options granted

Restricted stock units

92,300 shares

Aggregate RSUs granted

Option term

10 years

Term of the stock options

Option vesting period

4 years

Scheduled vesting, subject to continued service

RSU vesting period

4 years

Scheduled vesting in four equal annual installments, subject to continued service

Historical Context

1 past event · Latest: Sep 17

1 event

1. Sep 17

   Inducement equity grants

   24h Move

   -5.3%

   Earlier awards used the same option and restricted-stock-unit structure for 14 newly hired employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-statutory stock options financial

"non-statutory stock options to purchase up to an aggregate of 290,100 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"restricted stock units with respect to an aggregate of 92,300 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 290,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on October 20, 2026, and restricted stock units with respect to an aggregate of 92,300 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
media@dyne-tx.com 
781-317-1938

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Dyne Therapeutics grant to newly hired employees?

Dyne granted 16 newly hired employees options to purchase up to 290,100 shares and restricted stock units covering 92,300 shares. The awards were a material inducement to accept employment under Nasdaq Listing Rule 5635(c)(4).

What are the vesting terms for Dyne Therapeutics’ inducement awards?

Both award types vest over four years, subject to continued service through each vesting date. Options vest 25% on the first anniversary of the employee’s start date, then in 12 equal quarterly installments. Restricted stock units vest in four equal annual installments from the employee’s start date. Options have a ten-year term.